Controlled in Vitro Release of Levodopa from Sodium Alginate Membranes

Margarida Franco, Sara Biscaia, Tânia Viana, Nuno Alves, Pedro Morouço


Levodopa (LD) plays a central role in Parkinson’s Disease therapeutics. In this study, we aimed to encapsulate LD in
sodium alginate (SA) membranes, and to study its dissolution profiles. Two types of SA membranes, loaded with two
different amounts of LD were prepared and compared (M1: 85 mg per 50 ml SA/LD; M2: 127.5 mg per 75 ml SA/LD);
membranes production followed a solvent-casting methodology. Calcium chloride was used as a crosslinking agent. LD
solubility tests were performed to predict sink conditions required for complete drug dissolution. LD dissolution assays
were carried out and UV spectrophotometry was used for cumulative release percentage determination. The obtained data
were mathematically evaluated and fitted into mathematical dependent models; the difference factor (f1), the similarity
factor (f2) and other parameters like dissolution efficiency (DE) were also used. No differences in the dissolution profiles
of both membranes were noticed. Thus, increasing the amount of LD, but keeping the same concentration, led to a similar
controlled release. The membranes presented in this work are expected to be a promising contribution in the development
of a new controlled drug delivery system for LD administration.


Parkinson’s disease, controlled delivery, dissolution assays, drug release kinetics, mathematical model fitting.

Full Text:




  • There are currently no refbacks.